


Formal Gold- and Rhodium-Catalyzed Regiodivergent C–H Alkynylation of 2-Pyridones

Yunyun Li, Fang Xie, and Xingwei Li*

Dalian Institute of Chemical Physics, Chinese Academy of Science, Dalian 116023, China

Supporting Information

ABSTRACT: Formal regiodivergent C-H alkynylation of 2pyridones bearing different *N*-substituents has been realized under Au(I) and Rh(III) catalysis using a hypervalent iodine alkyne reagent. When catalyzed by Au(I), the alkynylation occurred at the most electron-rich 5-position via an electrophilic alkynylation pathway. The selectivity was switched to the 6-position under assistance of an *N*-chelation group when a Rh(III) catalyst was employed. A rhodacylic complex has been isolated as a key intermediate.



T ransition-metal-catalyzed C–H activation is a rapidly evolving area that has attracted increasing attention over the past decades.¹ The C–H activation strategy has allowed both facile construction and derivatization of a large number of heterocycles that are known to exhibit biological activities.² Despite the great progress, the selective activation of a specific C–H bond remains a challenge, and ideally, different selectivities are controllable under different catalytic conditions, where this switch of selectivity may be correlated to different reaction mechanisms.

On the other hand, the 2-pyridone scaffold is a key structural motif widely found in a variety of natural and bioactive compounds.³ While a number of synthetic methods have been reported for the facile construction of the 2-pyridone rings using different transition metals,⁴ selective C-H functionalization of 2-pyridone rings can be challenging. In 2009, Nakao and Hiyama reported the selective functionalization of 2-pyridones at the 6-position with the assistance of a Lewis acid additive.⁵ Later, Gallagher achieved oxidative C-H olefination of a specific 2-pyridone at the 3-position.⁶ In 2012, we have reported both oxidative olefination and arylation at the 3- and 5-positions, and the selectivity can vary with the substituent in the 2-pyridone ring (substrate control).⁷ In 2014, the Miura group achieved the arylation of 2-pyridones at the 3-position via a radical pathway.⁸ In addition, Miura also realized the coppercatalyzed arylation of 2-pyridones at the 6-position,⁹ in which the coupling proceeded via a chelation-assisted C-H activation mechanism. Despite the progress, it remains distinctly challenging to selectively control and switch the site selectivity of 2-pyridones due to the electronic and steric similarity of C-H bonds in this substrate.


Different selectivities of C–H functionalization of indoles (C-2 and C-3) and other heterocycles have been extensively studied and offered important inspirations.¹⁰ Driven by the need to achieve diversified and switchable selectivity of diverse heterocycles, we aimed to explore the C–H alkynylation of 2-pyridones. Waser et al. demonstrated that electron-rich heterocycles reacted at the most electron-rich site with

hypervalent iodine alkynes and the reaction occurred via an electrophilic alkynylation mechanism.¹¹ We reasoned that the intrinsic electronic effect of the 2-pyridone rings may also allow the alkynylation to occur with distinct site selectivity. On the other hand, we and others have demonstrated that this alkynylating reagent can undergo facile coupling with both electron-rich and electron-poor arenes via a Rh(III)- and Ir(III)-catalyzed C–H activation mechanism.¹² The combination of these two distinct mechanisms should allow the controllable switch of the site selectivity. We now report the Au(I)- and Rh(III)-catalyzed C–H alkynylation of 2-pyridones at the 5- and 6-positions, respectively.

We initiated our C-H alkynylation studies with the optimization of the reaction conditions for the coupling of Nmethyl 2-pyridone (1a) with 1-(triisopropylsilyl)ethynyl-1,2benziodoxol-3(1H)-one (TIPS-EBX, 2a), and the results are given in Table 1. Au(I) catalysts were our first choice because Waser et al. demonstrated that Au(I) species displayed high activity in the alkynylation of a variety of electron-rich heteroarens.¹¹ However, using AuCl as the catalyst in the absence of any additive gave essentially no conversion (50 °C). The desired product 3a was observed when $Zn(OTf)_2$ was introduced as an additive (entry 2).^{11,12e} This product was fully characterized, and the alkynylation occurred exclusively at the most electron-rich 5-position. The observed site selectivity agrees with previous reports.^{6,7,13} The yield was slightly improved when the Zn(II) additive was replaced by a stoichiometric amount of TFA,^{11c} which likely activated both the catalyst and the alkynylating reagent, and the optimal amount of TFA was found to be 1.5 equiv (entries 3-5). Screening of solvents revealed 1,4-dioxane as the optimal one. The reaction was strongly temperature-dependent. Thus, increasing the temperature to 80 $^\circ C$ produced 3a in 92% isolated yield (entry 7). In contrast to the high efficiency of

Received: October 17, 2015 Published: December 28, 2015

Table 1. Optimization Studies^a




entry	catalyst (mol %)	additive (equiv)	solvent	temp (°C)	yield (%) ^b
1 ^{<i>d</i>}	AuCl (5)	none	MeCN	50	0
2 ^{<i>d</i>}	AuCl (5)	$Zn(OTf)_{2}$ (0.2)	MeCN	50	25
3	AuCl (5)	TFA (1)	MeCN	50	34
4	AuCl (5)	TFA (3)	MeCN	50	35
5	AuCl (5)	TFA (1.5)	MeCN	50	46
6	AuCl (5)	TFA (1.5)	dioxane	50	58
7	AuCl (5)	TFA (1.5)	dioxane	80	92
8	$AuCl_3(5)$	TFA (1.5)	MeCN	50	<5
9	$Au(PPh_3)Cl(5)$	TFA (1.5)	MeCN	50	40
10	$Pd(OAc)_2$ (5)	TFA (1.5)	MeCN	50	<5
11 ^{c,d}	$Pd(OAc)_2$ (5)	AgOAc (2)	dioxane	80	30


^aReaction conditions: **1a** (0.20 mmol), **2a** (0.24 mmol), AuCl (5 mol %), TFA (0.3 mmol), 1,4-dioxane (2.0 mL), 80 °C, 12 h, sealed tube under nitrogen. ^bIsolated yield after column chromatography. ^c(Bromoethynyl)triisopropylsilane was used instead of **2a**. ^dWithout TFA.

AuCl, other Au(I) and Au(III) catalysts only gave inferior results (entries 8, 9). Although palladium catalysts are among the first reported catalysts that can catalyze the alkynylative coupling between electron-rich heteroarenes and bromoalky-nynes,¹⁴ using Pd(OAc)₂ as a catalyst only gave poor conversions (entries 10, 11).

Having determined the optimal conditions, we next examined the scope and limitations of this coupling system (Scheme 1). Extension of the N-alkyl group has been successful, and a series of products were isolated in good to high yields (3a-3d). N-Aryl substituted 2-pyridones also underwent smooth coupling, albeit in lower yields. The reduced yields might be attributed to the lower nucleophilicity of substrates. However, we did not observe the electronic effect of the N-aryl substituent on the reaction yields. Various substituents on the pyridine ring are also tolerated. The coupling of an isoquinolone afforded the desired product (31) in 72% yield. Introduction of different substituents into the 3-, 4-, and 6-positions is well-tolerated, and the isolation of 3n and 3p in good yields indicates tolerance of steric hindrance. In contrast, the coupling between N-(2-pyridyl)pyridone and TIPS-EBX proceeded with low efficiency (3q).


We next turned to alkynylation of 2-pyridones assisted by an N-directing group. We reasoned that, in this case, the reaction may proceed via a chelation-assisted C-H activation pathway, leading to C(6)-alkynylation. Indeed, by following the Rh(III)catalyzed C-H alkynylation conditions that we have reported,^{12e} the coupling of N-(2-pyridyl)pyridone with TIPS-EBX proceeded smoothly at 80 °C, and the coupled product 5aa was isolated in 95% yield (Scheme 2). ¹H NMR analyses of the product confirmed the C(6)-selectivity, indicating a switch of the reaction mechanism. The scope of this coupling was next explored. Both electron-donating and electron-withdrawing groups at 3-, 4-, and 5-positions are tolerated. However, the substrate with a 5-methyl group failed to give the desired product. In line with the Au-catalyzed system, the 2-isoquinolone substrate also reacted with high efficiency (5la). Variation of the substituents at different positions of the pyridine ring revealed that the reaction was





^aReaction conditions: 2-pyridone (0.20 mmol), TIPS-EBX (0.24 mmol), AuCl (5 mol %), TFA (0.3 mmol), dioxane (2.0 mL), 80 °C, 12 h, sealed tube under nitrogen. ^bIsolated yield after column chromatography.

marginally affected, indicating that the electronic effects of the directing group had limited influence (5ha-5ka). The directing group is not limited to a pyridine ring, and the alkynyation of




Scheme 2. Rh(III)-Catalyzed Alkynylation of 2-Pyridones under Chelation Assistance^{a,b}

"Reaction conditions: 2-pyridone (0.20 mmol), TIPS-EBX (0.24 mmol), $[RhCp*Cl_2]_2$ (3 mol %), $Zn(OTf)_2$ (15 mol %), DCE (2.0 mL), 80 °C, 12 h, pressure tube under nitrogen. "Isolated yield after column chromatography." [RhCp*(MeCN)_3](SbF₆)₂ (8 mol %), DCM (2.0 mL), 80 °C, 12 h.

N-methylisoquinolone occurred at the *peri* position in moderate yield (**5ma**). The choice of a directing group is essential, and the 2-pyrimidyl ring failed to function as a directing group. The reaction also failed when *N*-methyl 2-pyridone was applied, indicating that the rhodium- and the gold-catalyzed reaction conditions are not switchable. The alkynylating reagent could be extended to TBDPS-EBX and ^tBu-EBX, although TMS- and Ph-EBX both failed to give the desired products, likely due to lack of steric protection.^{12e}


In addition to 2-pyridones, we also examined the alkynylation of a structurally related 4-pyridone substrate (6).^{10b} Under the same Rh(III)-catalyzed conditions, the coupling of *N*-(2-pyridyl)-4-pyridone with TIPS-EBX afforded product 7 in

59% yield (eq 1), where essentially no dialkynylation was detected.



Mechanistic studies have been performed (Scheme 3). To probe the Au(I)-catalyzed catalytic mechanism, H/D exchange was performed first (Scheme 3a). H/D exchange of 1a has been attempted under Au(I) catalysis using CD₃COOD as the deuterium source. However, essentially no exchange has been

Scheme 3. Mechanistic Consideration of Au-Catalyzed Alkynylation




detected. Then, the competition between 1k and 1f differing in electronic effect of the *N*-aryl group under the Au(I)-catalyzed conditions afforded 3ka and 3fa in a 0.68:1 ratio (Scheme 3b), indicating that an electron-donating group tends to favor the reaction. In a proposed mechanism of Au-catalyzed C–H alkynylation of 2-pyridone 1a, it is likely that 1a does not directly undergo auration. It may nucleophilically attack a Au(III) alkynyl intermediate generated from oxidative addition of a Au(I) species (oxidative addition–electrophilic auration mechanism, Scheme 3c).^{11b} Alternatively, it might act as a nucleophile to attack the activated alkyne (π -activation mechanism).^{11b}

In contrast, the Rh(III)-catalyzed H/D exchange of 4f in the presence of CD₃COOD was observed at the 6-position (D 50%), indicating the relevancy of C–H activation (Scheme 4a). To further explore the C–H activation process, 4a was allowed to react with a stoichiometric amount of [RhCp*Cl₂]₂ in the presence of NaOAc (Scheme 4b). Although the reaction failed to go to completion, rhodacyle 8 was isolated in 40% yield after column chromatography and was fully characterized. In particular, the Rh-C resonates characteristically at δ = 184 as a doublet in the ¹³C NMR spectrum. Complex 8 proved to be an active intermediate because, when catalyzed by 8 (6 mol %), the coupling of 4f with TIPS-EBX afforded the product 5fa in 82% yield (Scheme 4c). Next, several substrate competition reactions were carried out. In the competition between 4f and 4g under the Rh(III) conditions (Scheme 4d), the more

electron-rich substrate 4f also reacted at a higher rate. In a competition reaction between 4a and a typical a 2-arylpyridine (9, Scheme 4e), the 2-pyridone 4a reacted at a slightly higher rate, indicative of the comparable reactivity of these two substrates. On the basis of the preliminary results and literature precedents,^{11,12} a plausible mechanism of the Rh(III)-catalyzed C-H alkynylation reaction is given in Scheme 4f. Cyclometalation of 2-pyridone 4a gives a rhodacycle A. Subsequent oxidative addition of the C-I bond in the R-EBX reagent affords a Rh(V) alkynyl benzoate intermediate B, which undergoes C-C reductive elimination to release the alkynylated product together with a Rh(III) benzoate intermediate C. Protonolysis of C released the 2-iodobenzoate byproduct and regenerated the Rh(III) catalyst.

Derivatization of the coupled product has been performed to demonstrate the synthetic usefulness of this method. Treatment of **5fa** with TBAF led to facile desilylation, and the product **6fa** was isolated in 85% yield (eq 2). Treatment of **5fa** with MeOTf, followed by base treatment of the methylated intermediate, afforded the deprotected NH 2-pyridone **7fa** in 56% overall yield (eq 3). Thus, the *N*-pyridyl ring represents a removable directing group.




In summary, we have realized formal regiodivergent C-H alkynylation of different 2-pyridones under Au(I) and Rh(III) catalysis. Under the Au(I) conditions, the alkynylation occurred at the most electron-rich 5-position via an electrophilic alkynylation pathway, while the selectivity was switched to the 6-position in the presence of a Rh(III) catalyst under assistance of an N-chelation group. A rhodacyclic intermediate has been isolated, and this coupling occurs via a C-H activation mechanism. The switch of the regioselectivity results from different mechanisms in a combination of different substrates and metal catalysts. Future studies are directed to regiodivergent functionalization of other heteroarenes via Rh(III)-catalyzed C-H activation.

EXPERIMENTAL SECTION

General Information. All chemicals were obtained from commercial sources and were used as received unless otherwise noted. 2-Pyridones¹⁵ and hypervalent iodine alkynes¹⁶ were prepared by following literature reports. All reactions were carried out using Schlenk techniques or in a nitrogen-filled glovebox. NMR spectra were recorded on a 400 MHz NMR spectrometer in the solvent indicated. The chemical shift is given in dimensionless δ values and is frequency referenced relative to TMS in ¹H and ¹³C NMR spectroscopy. HRMS data were obtained via ESI mode with a TOF mass analyzer. Column

Scheme 4. Mechanistic Consideration of Rh(III)-Catalyzed Alkynylation



chromatography was performed on silica gel (300–400 mesh) using ethyl acetate (EA)/petroleum ether (PE) or $MeOH/CH_2Cl_2$.

General Procedure for Synthesis of 3. 1-Methylpyridin-2(1H)one (0.20 mmol), alkynes (0.24 mmol), AuCl (5 mol %), TFA (0.3 mmol), and 1,4-dioxane (2 mL) were charged into a reaction tube. The reaction mixture was stirred at 80 °C for 12 h. After the mixture cooled to room temperature, the solvent was removed under reduced pressure and the residue was purified by silica gel chromatography using PE/EA to afford product 3.

1-Methyl-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3a**). Brown solid (53 mg, 92%, 0.18 mmol); mp 99–100 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, J = 2.4 Hz, 1H), 7.42 (dd, J = 9.4, 2.4 Hz, 1H), 6.57 (d, J = 9.4 Hz, 1H), 3.60 (s, 3H), 1.16 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 161.8, 142.2, 142.1, 120.2, 102.8, 102.0, 91.3, 37.7, 18.6, 11.2. HRMS: m/z: [M + H]⁺ calculated for C₁₇H₂₈NOSi⁺: 290.1935, found 290.1937.

1-*Ethyl*-5-((*triisopropylsilyl*)*ethynyl*)*pyridin*-2(1*H*)-one (**3b**). Yellow solid (34 mg, 56%, 0.11 mmol); mp 98–100 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.57 (d, J = 2.2 Hz, 1H), 7.40 (dd, J = 9.4, 2.3 Hz, 1H), 6.56 (d, J = 9.4 Hz, 1H), 4.04 (q, J = 7.2 Hz, 2H), 1.43 (t, J = 7.2 Hz, 3H), 1.17 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 161.1, 141.9, 140.9, 120.6, 102.9, 102.2, 91.1, 45.2, 18.6, 14.6, 11.2. HRMS: m/z: [M + H]⁺ calculated for C₁₈H₃₀NOSi⁺: 304.2091, found 304.2092.

1-Propyl-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3c**). Yellow solid (59 mg, 93%, 0.19 mmol); mp 101–103 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, J = 2.2 Hz, 1H), 7.40 (dd, J = 9.4, 2.4 Hz, 1H), 6.56 (d, J = 9.4 Hz, 1H), 3.94 (t, J = 7.4 Hz, 2H), 1.86 (m, 2H), 1.17 (apparent s, 21H), 1.03 (t, J = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.3, 141.9, 141.3, 120.6, 102.6, 102.3, 91.1, 51.6, 22.5, 18.6, 11.2, 11.0. HRMS: m/z: $[M + H]^+$ calculated for C₁₉H₃₂NOSi⁺: 318.2248, found 318.2250.

1-Benzyl-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3d**). Yellow solid (58 mg, 79%, 0.16 mmol); mp 114–115 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.50 (d, J = 2.3 Hz, 1H), 7.39–7.28 (m, 6H), 6.57 (d, J = 9.4 Hz, 1H), 5.12 (s, 2H), 1.09 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 161.4, 142.3, 141.1, 135.8, 129.0, 128.2, 128.1, 120.9, 103.3, 102.1, 91.6, 52.4, 18.6, 11.2. HRMS: m/z: [M + H]⁺ calculated for C₂₃H₃₂NOSi⁺: 366.2248, found 366.2250.

1-Phenyl-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3e**). Yellow solid (29 mg, 41%, 0.082 mmol); mp 102–103 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.57 (d, *J* = 2.4 Hz, 1H), 7.52–7.48 (m, 2H), 7.46–7.41 (m, 2H), 7.39–7.36 (m, 2H), 6.60 (d, *J* = 9.5 Hz, 1H), 1.10 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 161.3, 142.7, 141.8, 140.3, 129.5, 128.9, 126.6, 121.4, 103.2, 101.8, 91.9, 18.6, 11.2. HRMS: *m*/*z*: [M + H]⁺ calculated for C₂₂H₃₀NOSi⁺: 352.2091, found 352.2096.

1-(*p*-Tolyl)-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3f**). Yellow solid (43 mg, 59%, 0.12 mmol); mp 100–101 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, J = 2.3 Hz, 1H), 7.41 (dd, J = 9.4, 2.5 Hz, 1H), 7.30–7.23 (m, 4H), 6.59 (d, J = 9.4 Hz, 1H), 2.40 (s, 3H), 1.10 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 161.3, 142.4, 142.0, 138.9, 137.8, 130.1, 126.3, 121.4, 102.8, 102.0, 91.6, 21.2, 18.6, 11.2. HRMS: m/z: [M + H]⁺ calculated for C₂₃H₃₂NOSi⁺: 366.2248, found 366.2248.

1-(4-Methoxyphenyl)-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)one (**3g**). Yellow solid (31 mg, 41%, 0.082 mmol); mp 98–99 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, J = 2.4 Hz, 1H), 7.42 (dd, J = 9.5, 2.5 Hz, 1H), 7.28 (dt, J = 8.8 Hz, 2.0 Hz, 2H), 6.99 (dt, J = 8.8 Hz, 2.0 Hz, 2H), 6.59 (d, J = 9.5 Hz, 1H), 3.84 (s, 3H), 1.10 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 159.7, 142.5, 142.1, 133.1, 127.6, 121.3, 114.6, 102.9, 102.0, 91.7, 55.6, 18.6, 11.2. HRMS: m/z: [M + H]⁺ calculated for C₂₃H₃₂NO₂Si⁺: 382.2197, found 382.2197.

1-(4-Chlorophenyl)-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3h**). Yellow solid (59 mg, 76%, 0.15 mmol); mp 104–105 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, *J* = 2.4 Hz, 1H), 7.54 (dt, *J* = 8.6, 1.8 Hz, 2H), 7.49 (dd, *J* = 9.5, 2.4 Hz, 1H), 7.40 (dt, *J* = 8.6, 1.8 Hz, 2H), 6.66 (d, *J* = 9.5 Hz, 1H), 1.17 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 160.9, 142.7, 141.2, 138.6, 134.8, 129.6, 127.9, 121.5, 103.3, 101.6, 92.1, 18.6, 11.2. HRMS: *m*/*z*: [M + H]⁺ calculated for C₂₂H₂₉ClNOSi⁺: 386.1701, found 386.1702.

1-(4-Bromophenyl)-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3i**). Yellow solid (44 mg, 51%, 0.10 mmol); mp 129–130 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.63 (s, 1H), 7.62 (s, 1H), 7.52 (s, 1H), 7.43 (d, *J* = 9.5 Hz, 1H), 7.27 (d, *J* = 7.3 Hz, 2H), 6.60 (d, *J* = 9.5 Hz, 1H), 1.10 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 160.9, 142.8, 141.2, 139.2, 132.7, 128.3, 122.9, 121.5, 103.4, 101.6, 92.2, 18.6, 11.2. HRMS: *m/z*: [M + H]⁺ calculated for C₂₂H₂₉BrNOSi⁺: 430.1196, found 430.1198.

1-(4-Acetylphenyl)-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3***j*). Yellow solid (32 mg, 41%, 0.082 mmol); mp 103–105 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.15 (dt, *J* = 8.6, 1.8 Hz, 2H), 7.61 (d, *J* = 2.4 Hz 1H), 7.57 (dt, *J* = 8.6, 1.8 Hz, 2H), 7.50 (dd, *J* = 9.5, 2.4 Hz, 1H), 6.67 (d, *J* = 9.5 Hz, 1H), 2.70 (s, 3H), 1.16 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 196.8, 160.7, 143.9, 142.8, 140.8, 137.0, 129.5, 126.8, 121.6, 103.5, 101.5, 92.3, 26.7, 18.6, 11.2. HRMS: *m/z*: [M + H]⁺ calculated for C₂₄H₃₂NO₂Si⁺: 394.2197, found 394.2199.

1-(4-(*Trifluoromethyl*)*phenyl*)-5-((*triisopropylsilyl*)*ethynyl*)*pyridin*-2(1*H*)-one (**3***k*). Yellow solid (29 mg, 35%, 0.070 mmol); mp 65–67 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.78 (s, 1H), 7.76 (s, 1H), 7.55–7.53 (m, 3H), 7.45 (dd, *J* = 9.5, 2.4 Hz, 1H), 6.62 (d, *J* = 9.5 Hz, 1H), 1.10 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 160.7, 143.1, 142.9, 140.8, 131.0 (q, *J* = 32.9 Hz), 127.2, 126.7 (q, *J* = 3.8 Hz), 123.6 (q, *J* = 270.8 Hz), 121.7, 103.6, 101.4, 92.4, 18.6, 11.2. HRMS: *m/z*: [M + H]⁺ calculated for C₂₃H₂₉F₃NOSi⁺, 420.1965, found 420.1970.

2-Methyl-4-((triisopropylsilyl)ethynyl)isoquinolin-1(2H)-one (**3**). Yellow solid (49 mg, 72%, 0.14 mmol); mp 113–115 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (dd, *J* = 8.0, 0.6 Hz, 1H), 8.02 (d, *J* = 7.9 Hz, 1H), 7.82–7.75 (td, *J* = 1.8, 0.3 Hz, 1H), 7.62–7.55 (td, *J* = 2.0, 0.3 Hz,1H), 7.50 (s, 1H), 3.68 (s, 3H), 1.23 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 161.8, 137.3, 136.2, 132.6, 127.7, 127.4, 125.2, 125.0, 101.5, 100.8, 94.4, 37.2, 18.7, 11.3. HRMS: *m*/*z*: [M + H]⁺ calculated for C₂₁H₃₀NOSi⁺: 340.2091, found 340.2093.

1,3-Dimethyl-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3m**). Yellow solid (24 mg, 40%, 0.08 mmol); mp 67–70 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.48 (s, 1H), 7.30 (s, 1H), 3.60 (s, 3H), 2.20 (s, 3H), 1.17 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 162.3, 139.6, 139.1, 129.4, 102.6, 102.2, 90.6, 37.8, 18.6, 16.9, 11.2. HRMS: m/z: [M + H]⁺ calculated for C₁₈H₃₀NOSi⁺: 304.2091, found 304.2093.

1,4-Dimethyl-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3n**). Yellow solid (31 mg, 51%, 0.10 mmol); mp 104–106 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.54 (s, 1H), 6.45 (s, 1H), 3.57 (s, 3H), 2.32 (s, 3H), 1.17 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 161.8, 151.9, 141.5, 118.8, 104.5, 100.9, 94.2, 37.2, 20.6, 18.6, 11.2. HRMS: *m/z*: [M + H]⁺ calculated for C₁₈H₃₀NOSi⁺: 304.2091, found 304.2091. 4-(Benzyloxy)-1-methyl-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**30**). Yellow solid (26 mg, 33%, 0.066 mmol); mp 121–123 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.54 (s, 1H), 7.50–7.48 (m, 2H), 7.44–7.38 (m, 3H), 6.03 (s, 1H), 5.08 (s, 2H), 3.55 (s, 3H), 1.12 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 166.1, 142.3, 135.0, 128.5, 128.2, 127.5, 98.4, 98.1, 97.5, 94.7, 70.3, 36.9, 18.5, 11.2. HRMS: *m*/*z*: [M + H]⁺ calculated for C₂₄H₃₄NO₂Si⁺: 396.2353, found 396.2354.

1,6-Dimethyl-5-((triisopropylsilyl)ethynyl)pyridin-2(1H)-one (**3p**). Yellow solid (42 mg, 69%, 0.14 mmol); mp 64–65 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, J = 9.4 Hz, 1H), 6.48 (d, J = 9.4 Hz, 1H), 3.61 (s, 3H), 2.65 (s, 3H), 1.17 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 162.5, 150.5, 141.6, 117.0, 103.4, 102.5, 93.5, 31.8, 19.3, 18.6, 11.2. HRMS: m/z: [M + H]⁺ calculated for C₁₈H₃₀NOSi⁺: 304.2091, found 304.2092.

5-((*Triisopropylsilyl*)*ethynyl*)-2*H*-[1,2'-*bipyridin*]-2-one (**3q**). Waxy yellow solid (13 mg, 18%, 0.036 mmol). ¹H NMR (400 MHz, CDCl₃) δ 8.60 (d, *J* = 4.7 Hz, 1H), 8.09 (d, *J* = 2.2 Hz, 1H), 7.89 (d, *J* = 8.0 Hz, 1H), 7.87–7.82 (m, 1H), 7.42 (dd, *J* = 9.5, 2.4 Hz, 1H), 7.37–7.32 (m, 1H), 6.60 (d, *J* = 9.5 Hz, 1H), 1.10 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 160.9, 151.3, 149.1, 142.9, 140.0, 137.9, 123.5, 121.7, 121.5, 103.6, 102.0, 91.7, 18.6, 11.2. HRMS: *m/z*: [M + H]⁺ calculated for C₂₁H₂₉N₂OSi⁺: 353.2044, found 353.2045.

General Procedure for Synthesis of 5. 2H-[1,2'-Bipyridin]-2one (0.2 mmol), alkynes (0.24 mmol), [RhCp*Cl₂]₂ (3 mol %), Zn(OTf)₂ (15 mol %), and DCE (2 mL) were charged into a pressure tube. The reaction mixture was stirred at 80 °C for 12 h. After cooling to room temperature, the solvent was removed under reduced pressure and the residue was purified by silica gel chromatography using PE/EA to afford the desired product **5**.

6-((*Triisopropylsily*))*ethyny*])-2*H*-[1,2'-*bipyridin*]-2-one (**5aa**). White solid (67 mg, 95%, 0.19 mmol); mp 65–67 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.70 (d, J = 3.8 Hz, 1H), 7.92 (td, J = 7.7, 1.9 Hz, 1H), 7.46–7.38 (m, 3H), 6.73 (dd, J = 9.3, 1.0 Hz, 1H), 6.61 (dd, J = 6.9, 1.1 Hz, 1H), 0.96 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 162.4, 152.1, 149.7, 139.3, 138.3, 130.7, 124.1, 123.5, 122.7, 112.5, 101.9, 98.3, 18.3, 10.9. HRMS: m/z: [M + H]⁺ calculated for C₂₁H₂₉N₂OSi⁺: 353.2044, found 353.2046.

4-Methyl-6-((triisopropylsilyl)ethynyl)-2H-[1,2'-bipyridin]-2-one (**5ba**). Yellow solid (56 mg, 76%, 0.15 mmol); mp 104–105 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.63 (d, *J* = 3.9 Hz, 1H), 7.85 (t, *J* = 7.6 Hz, 1H), 7.36–7.34 (m, 2H), 6.48 (s, 1H), 6.43 (s, 1H), 2.21 (s, 3H), 0.90 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 162.5, 152.2, 151.0, 149.7, 138.3, 129.5, 124.0, 123.7, 121.0, 115.2, 101.1, 98.4, 21.2, 18.4, 10.9. HRMS: *m/z*: $[M + H]^+$ calculated for C₂₂H₃₁N₂OSi⁺: 367.2200, found 367.2201.

4-(Benzyloxy)-6-((triisopropylsilyl)ethynyl)-2H-[1,2'-bipyridin]-2one (**5ca**). Yellow solid (91 mg, 99%, 0.20 mmol); mp 139–140 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.63 (d, *J* = 4.1 Hz, 1H), 7.84 (td, *J* = 7.8, 1.6 Hz, 1H), 7.40–7.34 (m, 7H), 6.38 (d, *J* = 2.5 Hz, 1H), 6.09 (d, *J* = 2.4 Hz, 1H), 5.04 (s, 2H), 0.89 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 166.7, 164.0, 152.0, 149.7, 138.3, 135.1, 130.5, 128.8, 128.5, 127.7, 124.1, 123.9, 107.9, 101.6, 99.8, 98.0, 70.4, 18.4, 10.9. HRMS: *m*/*z*: [M + H]⁺ calculated for C₂₈H₃₅N₂O₂Si⁺: 459.2462, found 459.2465.

4-(Trifluoromethyl)-6-((triisopropylsilyl)ethynyl)-2H-[1,2'-bipyridin]-2-one (**5da**). Yellow solid (71 mg, 84%, 0.17 mmol); mp 116–118 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.65 (dd, *J* = 4.8, 1.1 Hz, 1H), 7.90 (td, *J* = 7.8, 1.9 Hz, 1H), 7.43–7.38 (m, 2H), 6.94 (s, 1H), 6.65 (d, *J* = 1.7 Hz, 1H), 0.90 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 161.4, 151.4, 150.0, 141.4 (q, *J* = 33.9 Hz), 138.7, 132.5, 124.6,123.3, 121.8 (q, *J* = 272.7 Hz), 119.8 (q, *J* = 4.4 Hz), 107.3 (q, *J* = 2.8 Hz), 104.6, 97.3, 18.4, 10.8. HRMS: *m*/*z*: [M + H]⁺ calculated for C₂₂H₂₈F₃N₂OSi⁺: 421.1918, found 421.1919.

3-Methyl-6-((triisopropylsilyl)ethynyl)-2H-[1,2'-bipyridin]-2-one (**5ea**). Yellow solid (56 mg, 76%, 0.15 mmol); mp 93–95 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.68(dt, J = 4.8, 0.8 Hz, 1H), 7.89 (td, J = 7.7, 1.8 Hz, 1H), 7.44–7.40 (m, 2H), 7.26 (d, J = 7.0 Hz, 1H), 6.55 (d, J = 7.0 Hz, 1H), 2.22 (s, 3H), 0.94 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 162.8, 152.5, 149.6, 138.2, 136.4, 132.3, 128.0, 123.9,

The Journal of Organic Chemistry

123.5, 112.4, 100.5, 98.6, 18.3, 17.2, 10.9. HRMS: m/z: $[M + H]^+$ calculated for $C_{22}H_{31}N_2OSi^+$: 367.2200, found 367.2198.

3-Methoxy-6-((*triisopropylsilyl*)*ethynyl*)-2*H*-[1,2'-*bipyridin*]-2-one (**5fa**). Yellow solid (61 mg, 80%, 0.16 mmol); mp 127–129 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.65 (ddd, *J* = 4.8, 1.8, 0.8 Hz, 1H), 7.88 (td, *J* = 7.8, 1.9 Hz, 1H), 7.42–7.38 (m, 2H), 6.65 (d, *J* = 7.8 Hz, 1H), 6.57 (d, *J* = 7.7 Hz, 1H), 3.88 (s, 3H), 0.93 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 157.8, 151.9, 151.4, 149.6, 138.3, 124.1, 123.5, 121.9, 112.3, 112.0, 99.1, 98.6, 56.1, 18.4, 10.9. HRMS: *m*/*z*: [M + H]⁺ calculated for C₂₂H₃₁N₂O₂Si⁺: 383.2149, found 383.2150.

3-(*Trifluoromethyl*)-6-(*îtriisopropylsilyl*)*ethynyl*)-2*H*-[1,2'-*bipyridin*]-2-*one* (**5***ga*). Yellow solid (76 mg, 90%, 0.18 mmol); mp 130–132 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.64 (dd, *J* = 4.7, 0.7 Hz, 1H), 7.88 (td, *J* = 7.8, 1.8 Hz, 1H), 7.75 (d, *J* = 7.4 Hz, 1H), 7.42–7.39 (m, 2H), 6.59 (d, *J* = 7.4 Hz, 1H), 0.90 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 151.2, 149.9, 138.8 (q, *J* = 5.0 Hz), 138.6, 134.7, 124.6, 123.5, 122.4 (q, *J* = 270.2 Hz), 121.8 (q, *J* = 31.1 Hz), 110.3, 105.8, 97.4, 18.3, 10.8. HRMS: *m/z*: [M + H]⁺ calculated for C₂₂H₂₈F₃N₂OSi⁺: 421.1918, found 421.1920.

5'-Methyl-6-((triisopropylsilyl)ethynyl)-2H-[1,2'-bipyridin]-2-one (**5ha**). Yellow solid (67 mg, 92%, 0.18 mmol); mp 80–81 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 7.65 (dd, J = 8.0, 2.0 Hz, 1H), 7.33 (dd, J = 9.3, 6.9 Hz, 1H), 7.28 (d, J = 7.9 Hz, 1H), 6.67 (d, J = 8.8 Hz, 1H), 6.54 (d, J = 6.9 Hz, 1H), 2.38 (s, 3H), 0.90 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 162.6, 150.1, 149.8, 139.4, 138.9, 134.2, 131.0, 122.8, 122.7, 112.5, 101.7, 98.4, 18.3, 10.9. HRMS: m/z: [M + H]⁺ calculated for C₂₂H₃₁N₂OSi⁺: 367.2200, found 367.2201.

5'-(Trifluoromethyl)-6-((triisopropylsilyl)ethynyl)-2H-[1,2'-bipyridin]-2-one (**5ia**). Yellow solid (71 mg, 84%, 0.17 mmol); mp 100–101 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.91 (d, *J* = 1.4 Hz, 1H), 8.12 (dd, *J* = 8.3, 2.2 Hz, 1H), 7.57 (d, *J* = 8.2 Hz, 1H), 7.38 (dd, *J* = 9.4, 6.9 Hz, 1H), 6.69 (dd, *J* = 9.4, 0.9 Hz, 1H), 6.59 (dd, *J* = 6.9, 1.0 Hz, 1H), 0.89 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 162.2, 155.0, 147.0 (q, *J* = 4.0 Hz), 139.8, 135.8 (q, *J* = 3.4 Hz), 130.2, 127.2 (q, *J* = 33.0 Hz), 123.9, 123.1 (q, *J* = 271.0 Hz), 122.8, 112.9, 102.9, 100.0, 97.9, 18.3, 10.9. HRMS: m/z: [M + H]⁺ calculated for C₂₂H₂₈F₃N₂OSi⁺: 421.1918, found 421.1920.

4'-Methyl-6-((triisopropylsilyl)ethynyl)-2H-[1,2'-bipyridin]-2-one (**5***ja*). Yellow solid (56 mg, 76%, 0.15 mmol); mp 97–98 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, J = 5.0 Hz, 1H), 7.38 (dd, J = 9.3, 6.9 Hz, 1H), 7.25 (s, 1H), 7.23 (d, J = 5.0 Hz, 1H), 6.72 (dd, J = 9.3, 1.0 Hz, 1H), 6.58 (dd, J = 6.9, 1.0 Hz, 1H), 2.45 (s, 3H), 0.95 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 162.5, 152.2, 150.1, 149.4, 139.3, 130.8, 125.2, 124.0, 122.7, 112.3, 101.6, 98.3, 20.9, 18.3, 10.8. HRMS: m/z: [M + H]⁺ calculated for C₂₂H₃₁N₂OSi⁺: 367.2200, found 367.2199.

4'-(Trifluoromethyl)-6-((triisopropylsilyl)ethynyl)-2H-[1,2'-bipyridin]-2-one (**5ka**). Yellow solid (82 mg, 97%, 0.19 mmol); mp 109–110 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.89 (d, *J* = 5.1 Hz, 1H), 7.71 (s, 1H), 7.66 (d, *J* = 5.1 Hz, 1H), 7.43 (dd, *J* = 9.4, 6.9 Hz, 1H), 6.74 (dd, *J* = 9.4, 1.0 Hz, 1H), 6.64 (dd, *J* = 6.9, 1.0 Hz, 1H), 0.94 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 162.2, 153.2, 150.8, 141.6 (q, *J* = 34.6 Hz), 139.7, 130.3, 122.8, 122.2 (q, *J* = 271.8 Hz), 120.0 (q, *J* = 3.2 Hz), 119.9 (q, *J* = 3.7 Hz), 112.8, 102.8, 97.9, 18.2, 10.8. HRMS: *m/z*: [M + H]⁺ calculated for C₂₂H₂₈F₃N₂OSi⁺: 421.1918, found 421.1917.

2-(*Pyridin-2-yl*)-3-((*triisopropylsily*))ethynyl)isoquinolin-1(2H)-one (**5***la*). Yellow solid (72 mg, 90%, 0.18 mmol); mp 119–120 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.66 (d, J = 4.8 Hz, 1H), 8.40 (d, J = 7.9 Hz, 1H), 7.87 (td, J = 7.7, 1.4 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.53–7.48 (m, 2H), 7.45 (d, J = 7.9 Hz, 1H), 7.37 (dd, J = 7.4, 4.9 Hz, 1H), 6.94 (s, 1H), 0.92 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 162.3, 152.5, 149.7, 138.3, 136.4, 133.0, 128.2, 127.9, 126.5, 126.1, 124.8, 124.1, 124.0, 113.5, 99.6, 99.3, 18.5, 11.0. HRMS: m/z: [M + H]⁺ calculated for C₂₅H₃₁N₂OSi⁺: 403.2200, found 403.2201.

2-Methyl-8-((triisopropylsilyl)ethynyl)isoquinolin-1(2H)-one (**5ma**). White solid (30 mg, 45%, 0.09 mmol); mp 88–90 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 7.4 Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.04 (d, J = 7.3 Hz, 1H), 6.35 (d, J = 7.3 Hz, 1H), 3.56 (s, 3H), 1.20 (apparent s, 21H). ¹³C NMR (100

MHz, CDCl₃) δ 161.3, 138.4, 135.1, 133.1, 130.7, 126.1, 126.05, 123.9, 107.1, 105.3, 97.6, 37.3, 18.8, 11.6. HRMS: m/z: [M + H]⁺ calculated for C₂₁H₃₀NOSi⁺: 340.2091, found 340.2095.

6-((tert-Butyldiphenylsilyl)ethynyl)-2H-[1,2'-bipyridin]-2-one (**5ab**). Yellow solid (44 mg, 51%, 0.10 mmol); mp 161–163 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.59–8.58 (m, 1H), 7.80 (td, J = 7.7, 1.9 Hz, 1H), 7.51 (dd, J = 8.0, 1.3 Hz, 4H), 7.44 (d, J = 7.9 Hz, 1H), 7.41–7.36 (m, 3H), 7.34–7.25 (m, SH), 6.72 (dd, J = 9.4, 1.0 Hz, 1H), 6.67 (dd, J = 6.9, 1.0 Hz, 1H), 0.90 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 162.4, 152.0, 149.9, 139.4, 138.5, 135.4, 131.9, 130.4, 129.8, 127.8, 124.3, 123.6, 123.4, 113.2, 100.3, 100.1, 26.9, 18.6. HRMS: m/z: [M + H]⁺ calculated for C₂₈H₂₇N₂OSi⁺: 435.1887, found 435.1885.

6-(3,3-Dimethylbut-1-yn)-2H-[1,2'-bipyridin]-2-one (**5ac**). Yellow solid (42 mg, 84%, 0.17 mmol); mp 141–142 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.66 (d, *J* = 4.6 Hz, 1H), 7.89 (t, *J* = 7.7 Hz, 1H), 7.42–7.32 (m, 3H), 6.64 (d, *J* = 9.3 Hz, 1H), 6.42 (d, *J* = 6.9 Hz, 1H), 0.95 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 162.8, 152.6, 149.5, 139.7, 138.3, 131.5, 124.0, 123.6, 121.6, 110.8, 108.0, 72.8, 29.9, 27.8. HRMS: *m*/*z*: [M + H]⁺ calculated for C₁₆H₁₇N₂O⁺: 253.1335, found 253.1336.

2-((*Triisopropylsilyl*)*ethynyl*)-4*H*-[1,2'-*bipyridin*]-4-one (**7**). Yellow waxy solid (42 mg, 59%, 0.12 mmol); ¹H NMR (400 MHz, CDCl₃) δ 8.63 (dd, *J* = 4.8, 1.0 Hz, 1H), 7.90 (td, *J* = 7.9, 1.8 Hz, 1H), 7.76 (d, *J* = 7.9 Hz, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.46 (dd, *J* = 7.4, 4.9 Hz, 1H), 6.78 (d, *J* = 2.7 Hz, 1H), 6.52 (dd, *J* = 7.9, 2.7 Hz, 1H), 1.01 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 178.8, 152.7, 149.4, 139.9, 138.2, 132.1, 124.2, 124.0, 121.0, 118.3, 103.5, 97.7, 18.3, 10.9. HRMS: *m/z*: $[M + H]^+$ calculated for C₂₁H₂₉N₂OSi⁺: 353.2044, found 353.2046.

Synthesis and Characterization of Rhodium(III) Complex 8. 2*H*-[1,2'-Bipyridin]-2-one (4a, 0.21 mmol), [RhCp*Cl₂]₂ (0.1 mmol), and NaOAc (0.6 mmol) were stirred overnight in CH₂Cl₂ (6 mL) at room temperature. The solvent was then removed under reduced pressure, and the residue was dissolved in CH₂Cl₂ and filtered to remove NaOAc. Column chromatography was performed on silica gel using ethyl acetate (EA)/petroleum ether (PE) = 4:1 to afford complex 8 in 40% yield (36 mg, 0.080 mmol). ¹H NMR (400 MHz, CDCl₃) δ 9.38 (d, *J* = 8.7 Hz, 1H), 8.59 (dd, *J* = 5.5, 1.2 Hz, 1H), 7.89–7.84 (m, 1H), 7.28 (dd, *J* = 6.2, 5.3 Hz, 1H), 7.16 (dd, *J* = 8.9, 6.9 Hz, 1H), 6.67 (dd, *J* = 6.8, 0.8 Hz, 1H), 6.18 (dd, *J* = 8.9, 0.9 Hz, 1H), 1.64 (s, 15H). ¹³C NMR (100 MHz, CDCl₃) δ 184.0 (d, *J*_{Rh-C} = 37.0 Hz), 166.2, 158.4, 150.1, 139.7, 139.1, 122.4, 118.8, 115.3, 114.3, 97.6 (d, *J*_{Rh-C} = 6.3 Hz), 9.1. HRMS: [M - Cl]⁺ calculated for C₂₀H₂₂N₂ORh⁺: 409.0787, found 409.0785.

Synthesis and Characterization of 6fa. Compound 6fa was obtained as a brown solid (39 mg, 85%, 0.17 mmol) by following a reported procedure.^{12e} mp: 101–102 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.66 (d, *J* = 3.8 Hz, 1H), 7.89 (td, *J* = 7.7, 1.7 Hz, 1H), 7.44–7.37 (m, 2H), 6.60 (dd, J = 17.6, 7.7 Hz, 2H), 3.87 (s, 3H), 2.05 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 157.8, 151.8, 151.6, 149.5, 138.4, 124.3, 123.6, 120.7, 112.8, 111.7, 83.9, 76.2, 56.2. HRMS: *m/z*: $[M + H]^+$ calculated for C₁₃H₁₁N₂O₂⁺: 227.0815, found 227.0813.

Synthesis and Characterization of 7fa. Compound 7fa was obtained as a brown solid by following a reported procedure.⁹ mp: 139–141 °C. ¹H NMR (400 MHz, CDCl₃) δ 6.50 (d, *J* = 7.7 Hz, 1H), 6.31 (d, *J* = 7.6 Hz, 1H), 3.76 (s, 3H), 1.04 (apparent s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 158.1, 151.4, 119.4, 113.1, 111.5, 98.8, 96.2, 55.9, 18.6, 11.1. HRMS: *m/z*: [M + H]⁺ calculated for C₁₇H₂₈NO₂Si⁺: 306.1884, found 306.1883.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b02410.

Experimental procedures and copies of NMR spectra of all new compounds (PDF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: xwli@dicp.ac.cn.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the Dalian Institute of Chemical Physics, Chinese Academy of Sciences, and the NSFC (Nos. 21472186 and 21272231) for financial support.

REFERENCES

(1) (a) Ackermann, L. Acc. Chem. Res. 2014, 47, 281. (b) Chen, X.; Engle, K. M.; Wang, D. H.; Yu, J.-Q. Angew. Chem., Int. Ed. 2009, 48, 5094. (c) Chen, Z.; Wang, B.; Zhang, J.; Yu, W.; Liu, Z.; Zhang, Y. Org. Chem. Front. 2015, 2, 1107. (d) Colby, D. A.; Bergman, R. G.; Ellman, J. A. Chem. Rev. 2010, 110, 624. (e) Kuhl, N.; Hopkinson, M. N.; Wencel-Delord, J.; Glorius, F. Angew. Chem., Int. Ed. 2012, 51, 10236. (f) Lyons, T. W.; Sanford, M. S. Chem. Rev. 2010, 110, 1147. (g) Song, G.; Li, X. Acc. Chem. Res. 2015, 48, 1007. (h) Song, G.; Wang, F.; Li, X. Chem. Soc. Rev. 2012, 41, 3651. (i) Wencel-Delord, J.; Dröge, T.; Liu, F.; Glorius, F. Chem. Soc. Rev. 2011, 40, 4740. (j) Wencel-Delord, J.; Glorius, F. Nat. Chem. 2013, 5, 369.

(2) (a) Wu, X.-F.; Neumann, H.; Beller, M. Chem. Rev. 2013, 113, 1. (b) Thansandote, P.; Lautens, M. Chem. - Eur. J. 2009, 15, 5874. (c) Satoh, T.; Miura, M. Chem. - Eur. J. 2010, 16, 11212. (d) Rouquet, G.; Chatani, N. Angew. Chem., Int. Ed. 2013, 52, 11726. (e) Liang, Y.; Liang, Y.-F.; Jiao, N. Org. Chem. Front. 2015, 2, 403. (f) Kurahashi, T.; Matsubara, S. Acc. Chem. Res. 2015, 48, 1703. (g) Godoi, B.; Schumacher, R. F.; Zeni, G. Chem. Rev. 2011, 111, 2937.

(3) (a) Dragovich, P. S.; Prins, T. J.; Zhou, R.; Brown, E. L.; Maldonado, F. C.; Fuhrman, S. A.; Zalman, L. S.; Tuntland, T.; Lee, C. A.; Patick, A. K.; Matthews, D. A.; Hendrickson, T. F.; Kosa, M. B.; Liu, B.; Batugo, M. R.; Gleeson, J.-P. R.; Sakata, S. K.; Chen, L.; Guzman, M. C.; Meador, J. W., III; Ferre, R. A.; Worland, S. T. J. Med. Chem. 2002, 45, 1607. (b) Adam, W.; Hartung, J.; Okamoto, H.; Marquardt, S.; Nau, W. M.; Pischel, U.; Saha-Möller, C. R.; Špehar, K. J. Org. Chem. 2002, 67, 6041. (c) Surup, F.; Wagner, O.; von Frieling, J.; Schleicher, M.; Oess, S.; Muller, P.; Grond, S. J. Org. Chem. 2007, 72, 5085. (d) Fotiadou, A. D.; Zografos, A. L. Org. Lett. 2011, 13, 4592. (e) Amr, A.-G. E.; Abdulla, M. M. Bioorg. Med. Chem. 2006, 14, 4341.

(4) (a) Shi, L.; Yu, K.; Wang, B. Chem. Commun. 2015, 51, 17277. (b) Ackermann, L.; Lygin, A. V.; Hofmann, N. Org. Lett. 2011, 13, 3278. (c) Imase, H.; Noguchi, K.; Hirano, M.; Tanaka, K. Org. Lett. 2008, 10, 3563. (d) Hyster, T. K.; Rovis, T. Chem. Sci. 2011, 2, 1606. (e) Su, Y.; Zhao, M.; Han, K.; Song, G.; Li, X. Org. Lett. 2010, 12, 5462.

(5) Nakao, Y.; Idei, H.; Kanyiva, K. S.; Hiyama, T. J. Am. Chem. Soc. 2009, 131, 15996.

(6) Cheng, D.; Gallagher, T. Org. Lett. 2009, 11, 2639.

(7) Chen, Y.; Wang, F.; Jia, A.; Li, X. Chem. Sci. 2012, 3, 3231.

(8) Nakatani, A.; Hirano, K.; Satoh, T.; Miura, M. J. Org. Chem. 2014, 79, 1377.

(9) Odani, R.; Hirano, K.; Satoh, T.; Miura, M. Angew. Chem., Int. Ed. 2014, 53, 10784.

(10) Selected reports: (a) Qin, X.; Liu, H.; Qin, D.; Wu, Q.; You, J.; Zhao, D.; Guo, Q.; Huang, X.; Lan, J. Chem. Sci. 2013, 4, 1964. (b) Kang, D.; Hong, S. Org. Lett. 2015, 17, 1938. (c) Lee, S.; Mah, S.; Hong, S. Org. Lett. 2015, 17, 3864.

(11) (a) Brand, J. P.; Charpentier, J.; Waser, J. Angew. Chem., Int. Ed. 2009, 48, 9346. (b) Brand, J. P.; Chevalley, C.; Scopelliti, R.; Waser, J. Chem. - Eur. J. 2012, 18, 5655. (c) Brand, J. P.; Waser, J. Angew. Chem., Int. Ed. 2010, 49, 7304. (d) Li, Y.; Brand, J. P.; Waser, J. Angew. Chem., Int. Ed. 2013, 52, 6743. (e) Li, Y.; Waser, J. Beilstein J. Org. Chem. 2013, 9, 1763. (f) Tolnai, G. L.; Ganss, S.; Brand, J. P.; Waser, J. Org. Lett. 2013, 15, 112.

(12) (a) Ai, W.; Wu, Y.; Tang, H.; Yang, X.; Yang, Y.; Li, Y.; Zhou, B. Chem. Commun. 2015, 51, 7871. (b) Collins, K. D.; Lied, F.; Glorius, F. Chem. Commun. 2014, 50, 4459. (c) Feng, C.; Loh, T.-P. Angew. Chem., Int. Ed. 2014, 53, 2722. (d) Wang, H.; Xie, F.; Qi, Z.; Li, X. Org. Lett. 2015, 17, 920. (e) Xie, F.; Qi, Z.; Yu, S.; Li, X. J. Am. Chem. Soc. 2014, 136, 4780.

(13) Itahara, T.; Ouseto, F. Synthesis 1984, 1984, 488.

(14) (a) Kim, S. H.; Chang, S. Org. Lett. 2010, 12, 1868. (b) Tobisu, M.; Ano, Y.; Chatani, N. Org. Lett. 2009, 11, 3250. (c) Dudnik, A. S.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 2096. (d) Seregin, I. V.; Ryabova, V.; Gevorgyan, V. J. Am. Chem. Soc. 2007, 129, 7742.

(15) Modak, A.; Rana, S.; Maiti, D. J. Org. Chem. 2015, 80, 296.

(16) Chen, C. C.; Waser, J. Org. Lett. 2015, 17, 736.